Species of *Picramnia* genus are used in folk medicine to treat or prevent skin disorders, but only few species have been studied for biological activity and chemical composition. *P. gracilis* Tul. is a native species from Central and South America and although its fruits are edible, phytochemical analysis or medicinal uses of this species are not known. In the search of candidates to antileishmanial drugs, this work aimed to evaluate the antileishmanial activity of *P. gracilis* in *in vitro* and *in vivo* studies. Only ethanolic extract of fruits showed leishmanicidal activity. The majoritarian metabolite was 5,3'-hydroxy-7,4'-dimethoxyflavanone ether that exhibited high activity against *L. (V.) panamensis* (EC$_{50}$ 17.0 ± 2.8 mg/mL, 53.7 μM) and low toxicity on mammalian U-937 cells, with an index of selectivity >11.8. *In vivo* studies showed that the flavanone administered in solution (2 mg/kg/day) or cream (2%) induces clinical improvement and no toxicity in hamsters with CL. In conclusion, this is the first report about isolation of 5,3'-hydroxy-7,4'-dimethoxyflavanone of *P. gracilis* Tul. The leishmanicidal activity attributed to this flavanone is also reported for the first time. Finally, the *in vitro* and *in vivo* leishmanicidal activity reported here for 5,3'-hydroxy-7,4'-dimethoxyflavanone offers a greater prospect towards antileishmanial drug discovery and development.

1. Introduction

Leishmaniasis is a tropical disease caused by *Leishmania* parasites that affects about 12 million people in 99 countries. Approximately, 350 million people are at risk of infection and two million new cases occur yearly [1]. Despite high morbidity, therapeutic alternatives are very few and have serious drawbacks associated mainly with use of high doses and prolonged administration resulting in moderate to severe toxicity [2]. The presence of severe toxic reactions to conventional medication indicates the need for new therapies that cure leishmaniasis. Natural products of plant origin are potential tools for these discoveries and have been used for centuries to treat empirically parasitic diseases for people around the world, stimulating clinical and laboratory research [3].

*Picramnia* species (*Picramniaceae*, previously *Simaroubaceae*) are commonly used in folk medicine to treat or prevent dermatosis, external ulcers (sores), and skin irritations [4]. Phytochemical investigation in some of these *Picramnia*
species resulted in isolation of several metabolites [5, 6], mainly triterpenes [7–9], anthrones and anthraquinone glycosides [10–14], and oxanthrones [10–12, 15] with cytotoxic, antimicrobial, antifungal, or antiparasitic activities [16–18].

Picramnia gracilis Tul. is a native species of the Andean region in South and Central America [19]. Although fruits of P. gracilis Tul. are edible [20], reports about phytochemical analysis or medicinal uses of this species are not known. Moreover, there are no reports about antileishmanial activity of any of Picramnia species.

Motivated by the presence of metabolites with antiparasitic activity previously demonstrated in several Picramnia species and their traditional use in skin problems, this study aimed to discover antileishmanial activity and cytotoxicity in extracts and metabolites of leaves and fruits of P. gracilis Tul. Here, the presence of 3,3’-hydroxy-7,4’-dimethoxyflavanone in P. gracilis Tul. fruits and its antileishmanial activity in vitro and in vivo are reported for the first time.

2. Materials and Methods

2.1. General Experimental Procedures. 1H NMR and 13C NMR spectra (all in CDCl3) were recorded on Bruker AMX 300 NMR spectrometers, using TMS as internal standard. Silica gel 60 (Merck, 0.063–0.200 mesh) was used for column chromatography, and precoated silica gel plates (Merck, 60 F254, 0.2 mm) were used for TLC.

2.2. Plant Material. Plant material was collected in the village of Santa Elena, “Sector Silletero,” municipality of Medellin, department of Antioquia (Colombia), in January 2011 at 2540 m.o.s.l. A voucher specimen was deposited in the Herbarium of the University of Antioquia (number 4588, F. Alzate).

2.3. Preparation of Extracts and Partial Purification. Material was dried in an oven at 35°C for 48 hours. Powdered leaves (86 g) of P. gracilis Tul. were extracted successively with hexane, then dichloromethane and ethyl acetate, and finally ethanol in a percolator at room temperature and concentrated in vacuum to give the corresponding extract (2.35 (2.7%), 2540 (2.7%), and 200 (100, 50, 25, 12.5, and 6.25 µg/mL). Cells cultured in medium alone were used as negative control (no toxicity) while cells exposed to amphotericin B (AmB) were positive control (toxicity). Cells were incubated at 37°C, 5% CO2 for 72 hours; then, the effect of each product on the viability of cells was determined incubating exposed and unexposed cells for 3 hours with 10 µM of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide. The MTT was reduced by succinate mitochondrial dehydrogenase to purple formazan that was then solubilized with 100 µL/well isopropanol 50% and SDS 10% and its concentration was determined by optical density at 570 nm in a spectrometer (Benchmark BioRad). Each concentration of the product and unexposed cells was tested in triplicate in at least two different experiments.

The in vitro cytotoxicity was determined as the percentage of viability and growth inhibition obtained from the optical densities (O.D.) for each experimental condition using the formula: viability (%) = (O.D. treated cells/O.D. untreated cells) × 100, where O.D. of untreated cells correspond to 100% viability. In turn, growth inhibition (%) is calculated as 100 – % viability. Growth inhibition (%) data obtained for each experimental condition was used to calculate the lethal concentration 50 (LC50) by Probit analysis [23]. Compounds were classified using an arbitrary scale as follows: potentially toxic: LC50 < 100 µg/mL; moderately toxic: LC50 > 100 and < 200 µg/mL; and potentially nontoxic: LC50 > 200 µg/mL.

2.4. Studies In Vitro of Cytotoxicity. Cytotoxic activity of all extracts and pure compound was evaluated in the human U937 cell line by MTT method, as described previously [21, 22]. In brief, cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), and 1% of antibiotics (penicillin-streptomycin (10,000 U/mL) at 100,000 cells/mL and six concentrations of each product (200, 100, 50, 25, 12.5, and 6.25 µg/mL). Cells cultured in medium alone were used as negative control (no toxicity) while cells exposed to amphotericin B (AmB) were positive control (toxicity). Cells were incubated at 37°C, 5% CO2 for 72 hours; then, the effect of each product on the viability of cells was determined incubating exposed and unexposed cells for 72 hours; then, the effect of each product on the viability of cells was determined incubating exposed and unexposed cells for 3 hours with 10 µL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide. The MTT was reduced by succinate mitochondrial dehydrogenase to purple formazan that was then solubilized with 100 µL/well isopropanol 50% and SDS 10% and its concentration was determined by optical density at 570 nm in a spectrometer (Benchmark BioRad). Each concentration of the product and unexposed cells was tested in triplicate in at least two different experiments.

The in vitro cytotoxicity was determined as the percentage of viability and growth inhibition obtained from the optical densities (O.D.) for each experimental condition using the formula: viability (%) = (O.D. treated cells/O.D. untreated cells) × 100, where O.D. of untreated cells correspond to 100% viability. In turn, growth inhibition (%) is calculated as 100 – % viability. Growth inhibition (%) data obtained for each experimental condition was used to calculate the lethal concentration 50 (LC50) by Probit analysis [23]. Compounds were classified using an arbitrary scale as follows: potentially toxic: LC50 < 100 µg/mL; moderately toxic: LC50 > 100 and < 200 µg/mL; and potentially nontoxic: LC50 > 200 µg/mL.

2.5. Studies In Vitro of Antileishmanial Activity. The activity of each extract or metabolite obtained from P. gracilis Tul. was determined on Phorbol 12-myristate 13-acetate-differentiated U-937 cells infected with intracellular amastigotes of L. (V.) panamensis expressing the green fluorescent protein gene (MHOM/CO/87/UA140pIR-GFP) [24, 25]. One mL of cells was dispensed into each well of 24-well plate (300,000 cell/mL RPMI 1640 medium and 100 ng/mL). Plates were incubated at 37°C, 5% CO2 during 72 hours and then washed twice with phosphate buffer saline (PBS). U-937 cells were then infected with stationary phase promastigotes of L. (V.) panamensis in a proportion of 35:1 (parasites:cell). Plates were incubated...
for 3 hours at 34°C, 5% CO₂ and after incubation cells were washed twice with PBS and incubated again for 24 hours at 37°C, 5% CO₂. Infected cells were exposed to four serial concentration dilutions of each product (100, 25, 6.25, and 1.56 μg/mL RPMI 1640 medium). In parallel, cells incubated in medium alone were used as control of infection (negative control) and cells exposed to AmB were used as control of leishmanicidal activity (positive control). After 72 hours of incubation at 37°C, 5% CO₂ cells were removed using trypsin/EDTA solution and washed twice with PBS by centrifuging 10 min at 1100 rpm, 4°C. Then, cells were analyzed in an Argon laser flow cytometer (Cytomics FC 500MPL) by reading at 488 nm excitation and 525 nm emission. Ten thousand events were counted from each well. The percentage of infected cells was determined by dot plot analysis while the parasitic load was calculated by the mean fluorescence intensity using histogram analysis. Each concentration was assessed in triplicate in at least two independent experiments.

In vitro antileishmanial activity was determined as percentage of infection (viable parasites inside infected cells) according to the MFI units from flow cytometry analysis for each experimental condition using the formula: % infection = (FMI treated infected cells/FMI untreated infected cells) × 100, where FMI of untreated infected cells corresponds to 100% viable parasites. Then, % of reduction of infection was calculated using the formula: % inhibition = 100 – % infection. The % inhibition obtained for each experimental condition was used to calculate the effective concentration 50 (EC₅₀) by Probit analysis [23]. Compounds were classified according to their antileishmanial activity using an arbitrary scale as follows: active: EC₅₀ < 20 μg/mL; moderately active: EC₅₀ 20 and <50 μg/mL; or potentially nonactive: EC₅₀ > 50 μg/mL. The index of selectivity (IS) was calculated by correlating cytotoxicity with antileishmanial activity using the formula: IS = LC₅₀/EC₅₀.

2.6. Evaluation of Therapeutic Response and Toxicity of 5,3’ -Hydroxy-7,4’-dimethoxyflavanone In Vivo. The therapeutic response of flavanone was tested in the hamster (Mesocricetus auratus) model for CL [26]. Briefly, previously anesthetized (ketamine 40 mg/kg and xylazene 5 mg/kg) hamsters were inoculated in the dorsal skin with promastigotes of L. (V.) braziliensis (MHOM/CO/88/UA301-EpiR-GFP) (5 × 10⁵ parasites/100 μL PBS). Three experimental groups (n = 8 each) consisting of four males and four females, were coded accordingly: A: flavanone pure, B: 2% flavanone cream, and C: MA (positive control). Treatment with flavanone pure (40 μL per dose), flavanone cream (40 mg per dose), or MA (200 μg per dose) was initiated immediately after development of a typical ulcer (4–6 weeks after infection). Flavanone (groups A and B) was applied topically daily for 28 days. In turn, MA (20 μL, 10 mg/mL) was applied intralesionally, also every day for 28 days. Animal welfare was supervised daily during the study. Both areas of the ulcer and body weight were measured every two weeks from the beginning of the treatments to the end of the study (three months after completion of treatment). The overall time points of evaluation were pretreatment day (TD0), end of treatment (PTD0), and posttreatment days 30, 60, and 90 (PTD30, PTD60, and PTD90, resp.). At the end of the study, hamsters were humanely sacrificed and, after necropsy, liver and kidney biopsies were taken for histopathological studies. A skin biopsy (from the site where the injury occurred) was also taken to determine parasite load by qPCR.

The effectiveness of each treatment was assessed comparing the lesion sizes prior to and after treatments. Treatment outcome at the end of study was recorded as cure (healing of 100% of the area and complete disappearance of the lesion); clinical improvement (reducing the size of the lesion in >30% of the area); failure (increasing the size of the lesion); or relapse (reactivation of lesion after initial cure). To compare the effectiveness among groups of treatments an arbitrary score was assigned to each treatment: 3 = cure, 2 = clinical improvement, 1 = relapse, and 0 = failure.

The toxicity of flavanone pure, flavanone cream, or MA was evaluated according to hepatic and renal functions of hamsters in treated and untreated animals as described previously [26]. At day TD0 and day 8 of treatment (TD8), blood was drawn from the heart and serum was separated by centrifugation at 5000 × g for 2.3 min. The serum was stored at −80°C until use. Hepatic and renal functions were assessed by measuring the levels of alanine amino transferase (ALT), blood urea nitrogen (BUN), and creatinine using commercially available kits (Biosystems, Spain). The hepatic and renal functions were also evaluated in healthy (uninfected and untreated) hamsters. Toxicity of treatments was determined by comparing serum levels of ALT, BUN, and creatinine and postmortem histological changes in liver and kidney. Severity of histological changes was also graded as severe, moderate, or mild.

2.7. Quantification of Parasite Load. Quantification of parasites present in the lesions was based on amplification of a single copy gene of Leishmania DNA polymerase (housekeeping gene) using quantitative real time PCR (qPCR) and a standard curve as described elsewhere [27]. Initially, a 600 bp fragment of DNA of L. (V.) panamensis was amplified by conventional PCR (T1000 thermocycler, BioRad) and purified using QIAquick Gel Extraction Kit according to the manufacturer’s instructions and product was ligated to InsTAclone pTZ57R/T vector. Then, DH5 alpha cells (Invitrogen, USA) were transformed with the construct. The construct was purified and, then, qRT-PCR was set to amplify a 120 bp fragment within the 600 bp sequence initially cloned. The number of copies per plasmid was determined based on the size of the cloned fragment and the size of the insert. A standard curve ranging from 1 to 1 million parasites in log increases from 10 was established. The QuantiFast SYBR Green qRT-PCR kit (Qiagen Inc., USA) was used for qPCR. The PCR amplifications were performed in a SmartCycler II (Cepheid, Sunnyvale, CA, USA) using a final volume of 25 μL containing 100 ng of DNA, 12.5 μL of the reaction mix, 100 nmol/L of each primer, and nuclelease-free water. The amplification efficiency of each was measured using the PCR program LinReg. Tissue samples were weighted and lysed with 500 mL of lysis buffer (100 mM...
**Table 1: In vitro cytotoxicity and antileishmanial activity of Picramnia gracilis Tul.**

<table>
<thead>
<tr>
<th>Product</th>
<th>Biological activity (µg/mL)</th>
<th>IS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>LC&lt;sub&gt;50&lt;/sub&gt;</td>
<td>EC&lt;sub&gt;50&lt;/sub&gt;</td>
</tr>
<tr>
<td>E-EtOH-le</td>
<td>&gt;200.0</td>
<td>&gt;100.0</td>
</tr>
<tr>
<td>E-He-le</td>
<td>22.4 ± 5.4</td>
<td>&gt;22.4</td>
</tr>
<tr>
<td>E-DiCl-Me-le</td>
<td>29.1 ± 9.0</td>
<td>&gt;29.1</td>
</tr>
<tr>
<td>E-EtAc-le</td>
<td>&gt;200.0</td>
<td>&gt;100.0</td>
</tr>
<tr>
<td>E-EtOH-fr</td>
<td>&gt;200.0</td>
<td>35.7 ± 1.3</td>
</tr>
<tr>
<td>5,3'-Hydroxy-7,4'-dimethoxyflavanone</td>
<td>&gt;200.0</td>
<td>17.0 ± 2.8 (53.7 µM)</td>
</tr>
<tr>
<td>Amphotericin B</td>
<td>375 ± 76</td>
<td>0.06 ± 0.004</td>
</tr>
<tr>
<td>Meglumine antimoniate</td>
<td>≥1000.0</td>
<td>6.8 ± 0.5</td>
</tr>
</tbody>
</table>

Data represent the mean value ± SD of cytotoxicity in terms of 50% lethal concentration (LC<sub>50</sub>) and leishmanicidal activity in terms of 50% effective concentration (EC<sub>50</sub>). E-EtOH-fr: Ethanolic extract from fruit; E-EtOH-le: Ethanolic extract from leaves; E-DiCl-Me-le: Dichloromethane extract from leaves; E-He-le: hexane extract from leaves; and E-EtAc-le: ethyl acetate extract from leaves. IS (index of selectivity) = LC<sub>50</sub>/EC<sub>50</sub>.

2.8. Data Analysis. For each parameter, average values with standard deviations (mean ± SD) were calculated. Data were analyzed by a two-way ANOVA. Differences were considered significant if P < 0.05. Statistical analysis was performed with Prism 6.0 (Graphpad Prism, San Diego, CA, USA).

3. Results

A majoritarian compound (4.4% yield) was identified as 5,3'-hydroxy-7,4'-dimethoxyflavanone, after NMR analysis and high resolution mass (Figure 1).

Ethanolic and ethyl acetate extracts from leaves (E-EtOH-le and E-EtAc-le) and ethyl acetate extract from fruit (E-EtOH-fr) were potentially nontoxic for U-937 cells (LC<sub>50</sub> > 200 µg/mL) (Table 1) while hexane and dichloromethane extracts from leaves (E-He-le and E-DiCl-Me-le, resp.) were highly cytotoxic (LC<sub>50</sub> 22.4 and 29.1 µg/mL, resp., as shown in Table 1). AmB, which is a highly cytotoxic drug, showed a LC<sub>50</sub> of 37.5 µg/mL, while MA was nontoxic on U-937 (LC<sub>50</sub> > 1000.0 µg/mL). The 5,3'-hydroxy-7,4'-dimethoxyflavanone did not exhibit cytotoxicity on human macrophages (LC<sub>50</sub> > 200 µg/mL).

Data represent the mean value ± SD of cytotoxicity in terms of 50% lethal concentration (LC<sub>50</sub>) and leishmanicidal activity in terms of 50% effective concentration (EC<sub>50</sub>); E-EtOH-fr: Ethanolic extract from fruit; E-EtOH-le: Ethanolic extract from leaves; E-DiCl-Me-le: Dichloromethane extract from leaves; E-He-le: hexane extract from leaves; and E-EtAc-le: ethyl acetate extract from leaves; IS (index of selectivity) = LC<sub>50</sub>/EC<sub>50</sub>.

The E-EtOH-fr showed moderate leishmanicidal activity on intracellular amastigotes of *L. (V.) panamensis* (EC<sub>50</sub> 35.7 µg/mL) (Table 1), while E-EtOH-le and E-EtAc-le were nonactive against intracellular amastigotes of *L. (V.) panamensis* (EC<sub>50</sub> > 100 µg/mL). Unfortunately, E-He-le and E-DiCl-Me-le (EC<sub>50</sub> > 22.4 and > 29.1 µg/mL, resp.) had leishmanicidal activity at concentrations that are toxic to cells that are the host cells for *Leishmania* parasites. As expected, AmB and MA were highly active against intracellular amastigotes of *L. (V.) panamensis* (EC<sub>50</sub> 0.06 and 6.8 µg/mL, resp.). The 5,3'-hydroxy-7,4'-dimethoxyflavanone showed high antileishmanial activity (EC<sub>50</sub> 17.0 µg/mL, 53.7 µM). This biological activity of 5,3'-hydroxy-7,4'-dimethoxyflavanone was highly selective with an IS > 11.8 while in extracts from fruit and leaves the IS was < 2.0 (Table 1). AmB and MA had an IS of 625.0 and >1471, respectively.

Treatment of *L. (V.) braziliensis* 40 µL/2 mg/kg body weight/day for 28 days with flavanone (group A) resulted in clinical improvement in 4/6 hamsters with 40 to 80% of reduction in their lesion sizes, failure in 1/6 hamsters, and relapse in 1/6 hamsters. Parasite load in this group of animals was 392.3 + 192.7 parasites/mg of tissue. On the other hand, treatment with 40 mg/2% flavanone cream/day for 28 days (group B) produced cure in 2/6 hamsters (with 100% reduction of lesion size); clinical improvement (>80% of reduction in their lesion size) was observed in 2/6 hamsters.

![Figure 1: Chemical structure of 5,3'-hydroxy-7,4'-dimethoxyflavanone isolated from fruits of Picramnia gracilis Tul.](image-url)
and relapse was in 2/8 hamsters (reactivation of ulcer after initial cure at PTD45 or PTD75). In this group parasite load was 2405.0 ± 4312.6 parasites/mg of tissue. Finally, treatment with intraleision injection of MA 200 μg/day/twice a week/28 days (group C) cured 5/6 hamsters and 1/6 hamster experienced relapse, 15 days after treatment. The amount of parasites in hamsters cured was 218.5 ± 393.7 parasites per mg of tissue. The parasite load in hamsters treated with flavanone solution (group A) was similar to that detected in hamsters treated with MA (group C), while it was different from that detected in hamsters treated with flavanone cream (group B). These differences were not statistically significant (P > 0.05).

Differences in treatment effectiveness were based on results obtained in each of the different stages of evaluation: end of treatment (PTD0) and PTD30, PTD60, and PTD90, using the arbitrary scale as described in the Materials and Methods. The mean value of treatment outcomes obtained at each time point for each treatment group is summarized in Figure 2. Effectiveness of topical treatment with topical flavanone pure (group A) was similar to that observed with intraleision injection of MA (group C) at any time point during follow-up except at PTD90 where response was higher in group C. Differences were not statistically significant (P > 0.05). On the other hand, the effectiveness of topical flavanone cream (group B) was higher than flavanone pure at PTD90. These differences were not statistically significant (P > 0.05).

Some animals in each treatment group experienced weight loss < 10%. Thus, loss weight was not associated with toxic effects of treatment with 5,3'-hydroxy-7,4'-dimethoxyflavanone. Levels of serum ALT for liver dysfunction and BUN and creatinine for renal dysfunction, measured 8 days upon treatment with this flavanone, as well as uninfected and untreated hamsters demonstrated increased levels of the serum of ALT and BUN after treatment with flavanone formulation, while creatinine levels were mildly increased after treatment with MA. However these levels were similar to those observed in hamsters infected but untreated (Table 2). Differences were not statistically significant (P > 0.05).

On the other hand, no histological alterations attributable to treatment were observed in animals treated with 5,3'-hydroxy-7,4'-dimethoxyflavanone. In contrast, hamsters treated with MA induced the following changes, which were observed in the liver: cloudiness, vacuolar and fat degeneration, karyomegaly, binucleation, and pigmentation. These occurred in moderate to severe degree. MA treatment also induced changes in kidney, including vacuolar and fat degeneration and binucleation in mild to moderate degree.

4. Discussion

Cutaneous leishmaniasis is an infectious disease that can cause serious psychologic and social stigma, especially when face and other visible areas of the body are compromised.
Hereby, in the search for new or better drugs to treat CL, antileishmanial activity and cytotoxicity products derived from leaves and fruit of *P. gracilis* Tul. were tested in *vitro*. Only ethanolic extract of fruit had moderate leishmanicidal activity and toxicity of the majoritarian compound of this extract was validated in *vitro*.

The majoritarian compound was identified as follows. This flavanone was previously isolated from *Chromolaena odorata* (L.) (Asteraceae) [28], *Artemisia campestris* subsp. *maritima* (Asteraceae) [29], and *Heliotropium glutinosum* Phil. (Heliotropiceae) [30] and named 5,3'-hydroxy-7,4'-dimethoxyflavanone. The possibility of metabolization by the host cell remains to be determined, antileishmanial activity of 5,3'-hydroxy-7,4'-dimethoxyflavanone on intracellular parasites may be related to its ability to chelate iron (Fe), depriving this essential nutrient from the intracellular forms [34].

The 5,3'-hydroxy-7,4'-dimethoxyflavanone administered at 2 mg/kg body weight/day (solution) or 2% (cream) during 28 days was able to induce cure or clinical improvement of CL in hamsters experimentally infected with *L. (V.) braziliensis*. Although effectiveness of flavanone was lower than MA in terms of treatment outcome at the end of the study, parasite load was similar in both groups of treatments. These results confirm that 5,3'-hydroxy-7,4'-dimethoxyflavanone is able to kill intracellular amastigotes of *L. (V.) braziliensis* present in the ulcer, but the efficacy is affected not only by dose but also by pharmaceutical formulation. None of the treatments produced detrimental effect on the body weight, histological morphology, or blood levels of ALT, BUN, and creatinine attributed to toxic effects of flavanone. Because the levels observed after treatment were similar to those in infected/untreated hamsters, variations are probably associated with *Leishmania* infection process. Moreover, nitrogen compounds may be increased due to the high degradation of amino acids or high-protein diets and are not always associated with an alteration in the kidney [35].

### 5. Conclusion

Hereby, the 5,3'-hydroxy-7,4'-dimethoxyflavanone is reported for the first time in one species of the Picramniaceae family. The activity against *L. (V.) panamensis* and *L. (V.) braziliensis* is also reported for the first time. Overall, bioassay
testing results observed in this investigation indicate that 5,3'-hydroxy-7,4'-dimethoxyflavanone isolated from *P. gracilis* Tul. represents promising antiprotozoal leads for further development of drugs to treat CL. Therapeutic response of this flavanone would be improved by increasing the amount of the active ingredient in the formulation, increasing the frequency of administration or extending the days of treatment. Finally, this work contributes with new knowledge chemical composition and novel biological activity of *P. gracilis* Tul., a native species from Central and South America.

**Abbreviations**

CL: Cutaneous leishmaniasis  
LC₅₀: Lethal concentration 50  
EC₅₀: Effective concentration 50  
IS: Index of selectivity.

**Ethical Approval**

The Institutional Ethical Committee for Animal Experimentation endorsed all procedures (Act no. 77-2012).

**Conflict of Interests**

The authors declare no conflict of interests.

**Acknowledgments**

Authors thank CV Mesa, for her help in biological assays. To Colciencias (CT-357-2011) and University of Antioquia (Cidepro and Estrategia de Sostenibilidad 2013-2014). They also thank Ms. A. Alvarez for language review.

**References**


Submit your manuscripts at http://www.hindawi.com